DAY 5:
Molnupiravir group had no significant difference in the SARS COV-2 RNA
error rate compared to the placebo arm (WMD: 2.53; 95% CI; [-1.04,
6.10] p=0.17; I²=46%). (Fig 2B)
Overall: A significant outcome reported with 400mg
molnupiravir (WMD: 2.27; 95% CI; 2.27 [0.50, 4.65] p=0.02; I²=0%).